BioMarin Pharmaceutical BMRN announced that the FDA has accepted the supplemental new drug application (sNDA) seeking full approval for Voxzogo (vosoritide) in children with achondroplasia, the most common form of dwarfism.
With the FDA accepting the sNDA for review, a decision from the regulatory body is expected on Feb. 28, 2027.
Voxzogo received an accelerated approval from the FDA in 2021 to treat children of all ages with achondroplasia. The drug is approved for similar indications in Europe, Japan and Australia.
The latest sNDA, which seeks to convert Voxzogo’s accelerated approval into full/traditional approval, is based on long-term safety and efficacy data from three ongoing studies, comprising adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm span, evaluated over long-term follow-up.
Per management, if approved, Voxzogo would become the first therapy for achondroplasia to convert from accelerated to traditional approval based on comprehensive clinical data, including adult height outcomes and other measures assessed over an extended follow-up period.
BMRN’s Stock Performance
Year to date, shares of BioMarin have lost 0.4% against the industry’s increase of 4.1%.
Image Source: Zacks Investment Research
BMRN Banks on Voxzogo Amid Growing Rivalry
Since its launch, Voxzogo has seen rapid uptake, driven by strong prescription demand. BioMarin expects to generate $0.98-$1.03 billion from Voxzogo sales in 2026.
BioMarin is also evaluating Voxzogo in the phase III CANOPY-HCH-3 study for a potential second indication, hypochondroplasia, which is generally considered to be a milder form of achondroplasia. In May 2026, the company reported positive data from this study, which achieved its primary and key secondary endpoints. Based on these results, BioMarin expects to submit a regulatory filing with the FDA in the third quarter of 2026.
If approved, the label expansion could broaden the drug’s addressable market opportunity.
However, the achondroplasia treatment market is becoming increasingly competitive.
In February 2026, the FDA approved Ascendis Pharma’s ASND Yuviwel for achondroplasia, marking the first direct competitor to Voxzogo. Before the approval of ASND’s Yuviwel, Voxzogo was the only FDA-approved therapy for the condition.
Meanwhile, BridgeBio Pharma BBIO is preparing to submit a regulatory filing to the FDA in the third quarter of 2026 for its investigational achondroplasia candidate, infigratinib. If approved, BBIO expects a potential launch for infigratinib in early to mid-2027.
Amid increasing competition, the successful development and potential label expansion of Voxzogo into additional indications could meaningfully strengthen BioMarin's long-term growth prospects.
BMRN’s Zacks Rank
BioMarin currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Ascendis Pharma A/S (ASND): Free Stock Analysis Report
BridgeBio Pharma, Inc. (BBIO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).